Paznib 400mg Tablet

Like most anticancer drugs, Paznib 400mg Tablet may cause some adverse effects on the body during the treatment. These can vary from mild to severe depending on the dose and the patient’s health condition.
Common side effects include:
Hypertension
Color change of hair and skin
High glucose levels
Difficulty in breathing
Decrease in weight and appetite
Diarrhea
Nausea and vomiting
Muscle and joint pain
Headache
Tiredness
Some serious side effects:
Frequent Infections
Bleeding from the anus and mouth
Hypothyroidism
Heart problems
Interstitial lung disease
Inform your doctor immediately if you experience any persistent or unusual side effects.

The dosage and treatment duration with Paznib 400mg Tablet is determined by the doctor as per the stage & type of cancer and the overall patient's health condition. It should be taken orally with water and should not be chewed, crushed, or broken. This capsule should be taken at least two hours after a meal or one hour before a meal at the fix time every day to get effective results. Don't miss a dose or overdose on the medicine.

Paznib 400mg Tablet is an anticancer medicine that belongs to the class of protein kinase inhibitors. This medicine works by binding and blocking the activity of the enzyme receptors (tyrosine kinase) that are responsible for the multiplication of the cancerous cells in the body. Paznib Tablet also stops the growth of new blood vessels within the tumor. It effectively slows down the progress.

It is advised not to miss any scheduled dosage of Paznib 400mg Tablet. In case you miss a dose, consult your doctor immediately.

Don't overdose to compensate for the missed one. Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.

It is advised not to drink grapefruit juice during the treatment with Paznib 400mg Tablet, as there is the possibility that it may increase the severity of the side effects of the medicine.

Always use effective contraception when any of the partners are undergoing treatment with Paznib 400mg Tablet or at least 2 weeks after the last dose of the medicine to prevent pregnancy.

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

1. Bukowski, R. M., Yasothan, U., & Kirkpatrick, P. (2010). Pazopanib. Nature reviews Drug discovery, 9(1), 17-18.
2. Miyamoto, S., Kakutani, S., Sato, Y., Hanashi, A., Kinoshita, Y., & Ishikawa, A. (2018). Drug review: pazopanib. Japanese Journal of Clinical Oncology, 48(6), 503-513.
3. Sonpavde, G., & Hutson, T. E. (2007). Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Current oncology reports, 9(2), 115-119.
4. Schutz, F. A., Choueiri, T. K., & Sternberg, C. N. (2011). Pazopanib: Clinical development of a potent anti-angiogenic drug. Critical reviews in oncology/hematology, 77(3), 163-171.
5. Hutson, T. E., Davis, I. D., Machiels, J. P. H., De Souza, P. L., Rottey, S., Hong, B. F., ... & Figlin, R. A. (2010). Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 28(3), 475-480.
6. Motzer, R. J., Hutson, T. E., Cella, D., Reeves, J., Hawkins, R., Guo, J., ... & Choueiri, T. K. (2013). Pazopanib versus sunitinib in metastatic renal-cell carcinoma. New England Journal of Medicine, 369(8), 722-731.